Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study

By afschroeder • July 13, 2026

Htoo PT, Cho H, Paik JM, Bykov K, Everett BM, Glynn RJ, Shay C, Schmedt N, Wexler DJ, Patorno E. Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study. Cardiovasc Diabetol. 2026 Jul 12. doi: 10.1186/s12933-026-03287-w. Epub ahead of print. PMID: 42437918.

Tags: cardiovascular disease, empagliflozin, General Internal Medicine, glucagon-like peptide-1 receptor agonist, heart failure, Nephrology, Publications, sodium-glucose cotransporter-2 inhibitor, Type 2 diabetes mellitus

The Exam Room as Sanctuary – Caring for Undocumented Patients

Linares MA, Liauw D, Cervantes L. The Exam Room as Sanctuary - Caring for Undocumented Patients. N Engl J Med. 2026 Jul 11. doi: 10.1056/NEJMp2603126.[...]

Coccidioidal peritonitis: A rare manifestation of disseminated coccidioidomycosis

Cheung N, Harmon R, Dietz RL Jr, Chandna S, Shoucri S. Coccidioidal peritonitis: A rare manifestation of disseminated coccidioidomycosis. IDCases. 2026 Jul 5;45:e02674. doi: 10.1016/j.idcr.2026.e02674.[...]

Comparison of Outcomes of Leadless Versus Transvenous Pacemakers Following Tricuspid Valve Surgery

Shimoda TM, Miyamoto Y, Ueyama HA, Itagaki S, Kaneko T, Gotanda H, Inoue K, Fukuhara S, Ailawadi G, Takayama H, Kuno T, Tsugawa Y. Comparison[...]